FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977286260> ?p ?o ?g. }

• W2977286260 endingPage "v316" @default.
• W2977286260 startingPage "v316" @default.
• W2977286260 abstract "Abstract Background To reveal candidate signaling pathways for targeted therapy in esophageal cancer (EC), and esophageal adenocarcinoma (EAC) in particular, we investigated key signal transduction pathways in material available in clinical routine, before and after neoadjuvant chemoradiation (nCRT), and for primary tumor and recurrent disease. Methods Paraffin-embedded material from three cohorts was used; (i) resectable EC; patients treated with an esophagectomy or receiving nCRT prior to resection, including cases with an available pre-nCRT biopsy of the primary tumor and corresponding resection; (ii) recurrent EC; patients of whom a resection and metachronous recurrence could be obtained. In addition, to explore the possibility to use patient-derived-xenografts (PDX) as a model to identify novel therapies, (iii) PDX of matched patient material was analyzed. Digitally annotated tumor areas ≥2 mm2 were transferred to a consecutive hematoxylin-stained slide and scraped for RNA extraction. Subsequently, a panel of qPCRs was performed, to infer signal transduction activity of the AR-, ER-, PI3K- (inverse of FOXO), HH-,TGF-β- and Wnt pathway. Results In pre-treatment EAC biopsies (i), high PI3K- and low TGF-β-pathway activity were correlated with poor pathological response. During treatment, a significant increase in PI3K- and decrease in TGF-β activity was observed in EAC poor nCRT responders compared to good responders (p = 0.003 and p = 0.042, respectively). Patients with a post-nCRT poor responder profile (high PI3K/ low TGF-β pathway activity) showed inferior disease free survival (median 17 vs. 97 months p = 0.055). Moreover, in nCRT treated patients, higher PI3K and lower TGF-β activities were seen in metachronous recurrences compared to resected tumors (ii) (p = 0.001 and p = 0.007, respectively). Pathway activity profiles were conserved between PDX and primary patient material (iii). Conclusions Loss of tumor-suppressive TGF-β and concurrent high PI3K pathway activity are associated with poor response to nCRT in EAC. This poor-responder profile is preserved in recurrences of nCRT pre-treated patients and PDX models, providing a valuable tool to experimentally test targeting candidate signal pathways such as PI3K. Legal entity responsible for the study Philips Research. Funding Philips Research. Disclosure L. Holtzer: Full / Part-time employment: Philips. M. Stoffels: Research grant / Funding (self), Full / Part-time employment: Philips. H. van Ooijen: Licensing / Royalties, Full / Part-time employment: Philips. A.G.C. van Brussel: Research grant / Funding (self), Licensing / Royalties, Full / Part-time employment: Philips. E.M.G. Aussems-Custers: Research grant / Funding (self), Licensing / Royalties, Full / Part-time employment: Philips. A. van de Stolpe: Licensing / Royalties, Full / Part-time employment: Philips. M.F. Bijlsma: Research grant / Funding (self): Celgene; Advisory / Consultancy: Servier. H.W.M. van Laarhoven: Advisory / Consultancy, Research grant / Funding (self): Celgene; Advisory / Consultancy, Research grant / Funding (self): BMS; Advisory / Consultancy, Research grant / Funding (self): Nordic; Advisory / Consultancy, Research grant / Funding (self): Lilly; Research grant / Funding (self): Merck Serono; Research grant / Funding (self): Bayer; Research grant / Funding (self): MSD; Research grant / Funding (self): Philips; Research grant / Funding (self): Roche. All other authors have declared no conflicts of interest." @default.
• W2977286260 created "2019-10-10" @default.
• W2977286260 creator A5000969662 @default.
• W2977286260 creator A5006582605 @default.
• W2977286260 creator A5012050627 @default.
• W2977286260 creator A5019027181 @default.
• W2977286260 creator A5019863663 @default.
• W2977286260 creator A5025579042 @default.
• W2977286260 creator A5030570166 @default.
• W2977286260 creator A5031825739 @default.
• W2977286260 creator A5034840800 @default.
• W2977286260 creator A5047714922 @default.
• W2977286260 creator A5079391859 @default.
• W2977286260 creator A5082821365 @default.
• W2977286260 creator A5090575821 @default.
• W2977286260 date "2019-10-01" @default.
• W2977286260 modified "2023-09-27" @default.
• W2977286260 title "Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer" @default.
• W2977286260 doi "https://doi.org/10.1093/annonc/mdz247.150" @default.
• W2977286260 hasPublicationYear "2019" @default.
• W2977286260 type Work @default.
• W2977286260 sameAs 2977286260 @default.
• W2977286260 citedByCount "0" @default.
• W2977286260 crossrefType "journal-article" @default.
• W2977286260 hasAuthorship W2977286260A5000969662 @default.
• W2977286260 hasAuthorship W2977286260A5006582605 @default.
• W2977286260 hasAuthorship W2977286260A5012050627 @default.
• W2977286260 hasAuthorship W2977286260A5019027181 @default.
• W2977286260 hasAuthorship W2977286260A5019863663 @default.
• W2977286260 hasAuthorship W2977286260A5025579042 @default.
• W2977286260 hasAuthorship W2977286260A5030570166 @default.
• W2977286260 hasAuthorship W2977286260A5031825739 @default.
• W2977286260 hasAuthorship W2977286260A5034840800 @default.
• W2977286260 hasAuthorship W2977286260A5047714922 @default.
• W2977286260 hasAuthorship W2977286260A5079391859 @default.
• W2977286260 hasAuthorship W2977286260A5082821365 @default.
• W2977286260 hasAuthorship W2977286260A5090575821 @default.
• W2977286260 hasBestOaLocation W29772862601 @default.
• W2977286260 hasConcept C121608353 @default.
• W2977286260 hasConcept C126322002 @default.
• W2977286260 hasConcept C143998085 @default.
• W2977286260 hasConcept C15152581 @default.
• W2977286260 hasConcept C185592680 @default.
• W2977286260 hasConcept C2779742542 @default.
• W2977286260 hasConcept C502942594 @default.
• W2977286260 hasConcept C55493867 @default.
• W2977286260 hasConcept C62478195 @default.
• W2977286260 hasConcept C71924100 @default.
• W2977286260 hasConcept C86803240 @default.
• W2977286260 hasConcept C95444343 @default.
• W2977286260 hasConceptScore W2977286260C121608353 @default.
• W2977286260 hasConceptScore W2977286260C126322002 @default.
• W2977286260 hasConceptScore W2977286260C143998085 @default.
• W2977286260 hasConceptScore W2977286260C15152581 @default.
• W2977286260 hasConceptScore W2977286260C185592680 @default.
• W2977286260 hasConceptScore W2977286260C2779742542 @default.
• W2977286260 hasConceptScore W2977286260C502942594 @default.
• W2977286260 hasConceptScore W2977286260C55493867 @default.
• W2977286260 hasConceptScore W2977286260C62478195 @default.
• W2977286260 hasConceptScore W2977286260C71924100 @default.
• W2977286260 hasConceptScore W2977286260C86803240 @default.
• W2977286260 hasConceptScore W2977286260C95444343 @default.
• W2977286260 hasLocation W29772862601 @default.
• W2977286260 hasOpenAccess W2977286260 @default.
• W2977286260 hasPrimaryLocation W29772862601 @default.
• W2977286260 hasRelatedWork W2249625608 @default.
• W2977286260 hasRelatedWork W2275543989 @default.
• W2977286260 hasRelatedWork W2328967333 @default.
• W2977286260 hasRelatedWork W2351696676 @default.
• W2977286260 hasRelatedWork W2353164399 @default.
• W2977286260 hasRelatedWork W2383116681 @default.
• W2977286260 hasRelatedWork W2388047550 @default.
• W2977286260 hasRelatedWork W2389086225 @default.
• W2977286260 hasRelatedWork W2801303331 @default.
• W2977286260 hasRelatedWork W3017137437 @default.
• W2977286260 hasVolume "30" @default.
• W2977286260 isParatext "false" @default.
• W2977286260 isRetracted "false" @default.
• W2977286260 magId "2977286260" @default.
• W2977286260 workType "article" @default.